Filtered By:
Source: TIME: Health
Management: Insurers
This page shows you your search results in order of date.
Order by Relevance | Date
Total 7 results found since Jan 2013.
FDA Approves New Menopause Drug for Hot Flashes
WASHINGTON — U.S. health regulators on Friday approved a new type of drug for women dealing with uncomfortable hot flashes caused by menopause.
The Food and Drug Administration approved the once-a-day pill from Astellas Pharma to treat moderate-to-severe symptoms, which can include sweating, flushing and chills.
Astellas’ drug, Veozah, uses a new approach, targeting brain connections that help control body temperature. The FDA said the medication will provide “an additional safe and effective treatment option for women,” in a statement.
More than 80% of women experience hot flashes during menopause,...
Source: TIME: Health - May 15, 2023 Category: Consumer Health News Authors: Matthew Perrone/AP Tags: Uncategorized Drugs healthscienceclimate wire Source Type: news
Here ’s an Alternative to Statins for Lowering Cholesterol
Statins have revolutionized heart disease by lowering cholesterol effectively—by up to 50% or more. But anywhere from 7% to 29% of people who take them may be more susceptible to its side effects, which include weakening of muscles and pain, and decide they can’t tolerate them. In a recent study published in JAMA Network Open, for example, researchers at Brigham and Women’s Hospital reported that more than 20% of patients seen at the hospital from 2000 to 2018 who were recommended to take statins refused to take them, and those who refused took three times as long to lower their LDL cholesterol to target ...
Source: TIME: Health - March 4, 2023 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized healthscienceclimate heart health Source Type: news
FDA Approves Lecanemab, a New Alzheimer ’s Drug
On Jan. 6, the U.S. Food and Drug Administration (FDA) approved a new drug to treat Alzheimer’s disease in its early stages.
Lecanemab, which will be available under the name Leqembi, can slow the cognitive decline associated with Alzheimer’s disease by 27%, according to data submitted to the FDA by the drug’s developers, Eisai and Biogen. It’s only the second medication to show any improvement in neurodegeneration, a key criterion in the FDA’s consideration for approval.
“For a long time, this is what we have been looking for,” says Dr. Sam Gandy, professor of neurology and psychi...
Source: TIME: Health - January 6, 2023 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized Drugs healthscienceclimate Source Type: news
Rural U.S. Hospitals Are On Life Support As a Third Wave of COVID-19 Strikes
When COVID-19 hit the Southwest Georgia Regional Medical Center in Cuthbert, a small rural town in Randolph County, in late March, the facility—which includes a 25-bed hospital, an adjacent nursing home and a family-medicine clinic, was quickly overwhelmed. In just a matter of days, 45 of the 62 nursing home residents tested positive. Negative residents were isolated in the hospital while the severely ill patients from both the nursing home and the local community were transferred to other better-equipped facilities.
“We were trying to get the patients out as fast as possible,” says Steve Whatley, Southwe...
Source: TIME: Health - October 20, 2020 Category: Consumer Health News Authors: Emily Barone Tags: Uncategorized COVID-19 Source Type: news
New Studies Give Mixed Results About Taking Fish Oil and Vitamin D
(CHICAGO) — Taking fish oil or vitamin D? Big studies give long-awaited answers on who does and does not benefit from these popular nutrients.
Fish oil taken by healthy people, at a dose found in many supplements, showed no clear ability to lower heart or cancer risks. Same for vitamin D.
But higher amounts of a purified, prescription fish oil slashed heart problems and heart-related deaths among people with high triglycerides, a type of fat in the blood, and other risks for heart disease. Doctors cheered the results and said they could suggest a new treatment option for hundreds of thousands of patients like these.
...
Source: TIME: Health - November 10, 2018 Category: Consumer Health News Authors: MARILYNN MARCHIONE / AP Tags: Uncategorized onetime Supplements Source Type: news
Depression Has Spiked By 33% In the Last Five Years, a New Report Says
Diagnoses of clinical depression — also known as major depression — have risen by 33% since 2013, according to a new report from health insurer Blue Cross Blue Shield.
The report, which was based on insurance claims filed by 41 million privately insured Blue Cross Blue Shield members, calls depression the “second most impactful condition on overall health for commercially insured Americans,” behind only high blood pressure. That’s because people with depression also tend to have other health issues, such as chronic illnesses and substance abuse, and as a result may have more significant health...
Source: TIME: Health - May 10, 2018 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized healthytime Mental Health/Psychology onetime Source Type: news
This Cholesterol Drug Combination Might Lower Your Risk of Death, Study Finds
(ORLANDO) — A newer cholesterol drug, used with older statin medicines, modestly lowered heart risks and deaths in a big study of heart attack survivors that might persuade insurers to cover the pricey treatment more often.
Results on the drug, Praluent, were announced Saturday at an American College of Cardiology conference in Florida. It’s the first time a cholesterol-lowering drug has reduced deaths since statins such as Lipitor and Crestor came out decades ago.
“It’s the ultimate outcome; it’s what matters to patients,” said study leader Dr. Philippe Gabriel Steg of Hospital Bichat i...
Source: TIME: Health - March 10, 2018 Category: Consumer Health News Authors: Marilyn Marchione / AP Tags: Uncategorized APH healthytime medicine onetime Source Type: news
